Provide a valuable resource to your clients or customers by linking to this resource page. Just place the following link on your website.
Buprenex was a trade name for buprenorphine hydrochloride injection containing 0.3 mg of buprenorphine per mL. It was used for pain severe enough to require an opioid when other treatment options were inadequate. DailyMed lists a November 1, 2023 marketing end date for the trade-name product. Generic buprenorphine hydrochloride injection remains marketed in the United States.
read more about buprenex ...Buprenorphine is a partial agonist at the mu-opioid receptor and an antagonist at the kappa-opioid receptor. Activation of mu-opioid receptors reduces perception of pain and produces opioid effects, including respiratory depression. After intramuscular injection, pharmacologic effects begin within about 15 minutes and persist for six hours or longer.
Buprenex was used for management of pain severe enough to require an opioid analgesic when alternate treatments were inadequate. Current generic buprenorphine hydrochloride injection carries the same pain indication. The injectable formulation is given intramuscularly or intravenously and is a Schedule III controlled substance.
For adults and patients older than 12 years, the labeled starting dose for buprenorphine injection is 0.3 mg by deep intramuscular or slow intravenous injection at intervals up to every six hours as needed. One additional dose up to 0.3 mg can be given 30 to 60 minutes after the first dose when clinically required.
Serious opioid risks include addiction, misuse, overdose, life-threatening respiratory depression, neonatal opioid withdrawal syndrome, and profound sedation or coma when combined with benzodiazepines, alcohol, or other central nervous system depressants. Other concerns include adrenal insufficiency, serotonin syndrome, low blood pressure, sleep-related breathing disorders, and withdrawal after abrupt discontinuation in physically dependent patients.
DailyMed lists a November 1, 2023 marketing end date for the trade-name product. Generic buprenorphine hydrochloride injection remains marketed.
Buprenex contained buprenorphine hydrochloride equivalent to 0.3 mg of buprenorphine per mL.
Buprenex was given by intramuscular or intravenous injection for severe pain requiring an opioid analgesic.
Yes. Buprenorphine hydrochloride injection is classified as a Schedule III controlled substance in the United States.
BUPRENEX (buprenorphine hydrochloride) injection. DailyMed. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b086772e-d15a-4d13-b1a2-38bfbde1f18c. Date Accessed September 18, 2026.
Buprenorphine. StatPearls. https://www.ncbi.nlm.nih.gov/books/NBK459126/. Date Accessed September 18, 2026.
Buprenorphine Hydrochloride Injection. DailyMed. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=adc1167e-910e-4d7b-abdc-751d3df0c3dc. Date Accessed September 18, 2026.
Buprenorphine Injection (Pain Relief). MedlinePlus. https://medlineplus.gov/druginfo/meds/a623028.html. Date Accessed September 18, 2026.
Controlled Substance Schedules. Drug Enforcement Administration. https://deaecom.gov/schedules/schedules.html. Date Accessed September 18, 2026.